Melanoma Clinical Trials in Pennsylvania

Showing 141-160 of 301 trials

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

NCT03665285

This research study is studying a new drug, NC318, as a possible treatment for advanced or metastatic solid tumors.

Advanced or Metastatic Solid TumorsLung CancerBreast Cancer+6 more

NextCure, Inc.109 participantsStarted Oct 2018

Los Angeles, California, United States • New Haven, Connecticut, United States • Hackensack, New Jersey, United States +3 more locations

COMPLETEDPhase 187 miles

PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma

NCT01621490

The purpose of this study is to evaluate pharmacodynamic changes of Nivolumab and Nivolumab in combination with Ipilimumab treatment on the biomarkers measured in the peripheral blood and tumor tissues of subjects with advanced melanoma (unresectable or advanced)

Advanced MelanomaMetastatic Melanoma

Bristol-Myers Squibb170 participantsStarted Sep 2012

Los Angeles, California, United States • Chicago, Illinois, United States • Lutherville, Maryland, United States +11 more locations

A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors

PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma

Melanoma Trials in Other Cities

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer

CD40 Agonistic Antibody APX005M (Sotigalimab) in Combination With Nivolumab

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)

Multi-center Phase I/IIa Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine in Addition to Standard of Care Checkpoint Inhibitor of Choice in Metastatic Melanoma Patients With Measurable Disease.

Study in Subjects With Small Primary Choroidal Melanoma

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

Study of the CD40 Agonistic Monoclonal Antibody APX005M

A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab

A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies

Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic Melanoma (V937-011)

Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors

A Rollover Study for Patients Who Received Tremelimumab in Other Protocols, to Allow the Patients Access to Tremelimumab Until This Agent Becomes Commercially Available or Development is Discontinued.

Study of PF-07263689 in Participants With Selected Advanced Solid Tumors

Neoadjuvant and Adjuvant Checkpoint Blockade

LGX818 and MEK162 in Combination With a Third Agent (BKM120, LEE011, BGJ398 or INC280) in Advanced BRAF Melanoma

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors

Other Conditions in Pennsylvania